Table 2.
Test parameter | C (n=24) | OC (n=19) | IC (n=47) | IMP (n=5) | P-value |
---|---|---|---|---|---|
Age (years) | 29.25±8.09 | 33.11±6.32 | 29.91±5.48 | 32.2±5.97 | NS |
Menarche age (years) | 16.07±2.56 | 16.38±3.56 | 16.81±0.52 | 16.2±0.73 | NS |
Duration of use (months) | – | 94.63±19.62 | 43.64±7.85 | 83.4±10.6 | NS |
SBP (mmHg) | 113.04±1.89 | 117.32±3.71 | 116.49±2.13 | 131.20±10.35 | NS |
DBP (mmHg) | 68.75±1.81*,† | 77.11±2.80 | 78.57±1.97* | 87.4±10.6† | 0.019*/0.025† |
BMI (kg/m2) | 21.73±0.75*,† | 26.4±1.12* | 25.24±0.63† | 22.30±0.94 | 0.003*/0.008† |
TC (mmol/L) | 3.35±0.62*,† | 4.33±0.96* | 4.00±0.91† | 3.77±0.66 | 0.002*/0.018† |
TG (mmol/L) | 0.66±0.24 | 0.83±0.31 | 0.80±0.51 | 0.82±0.12 | NS |
HDLC (mmol/L) | 1.31±0.25 | 1.3±0.25 | 1.35±0.39 | 1.20±0.26 | NS |
LDLC (mmol/L) | 1.74±0.57*,† | 2.65±0.94* | 2.29±0.80† | 2.21±0.80 | 0.002*/0.039† |
VLDLC (mmol/L) | 0.31±0.11 | 0.38±0.14 | 0.36±0.23 | 0.37±0.06 | NS |
TC/HDLCa | 2.63±0.13* | 3.46±0.27* | 3.12±0.13 | 3.32±0.47 | 0.026* |
LDLC/HDLCb | 1.39±0.56* | 2.15±1.05* | 1.82±0.76 | 2.00±0.96 | 0.014* |
Log (TG/HDLC)c | −0.33±0.25 | −0.22±0.22 | −0.27±0.26 | −0.16±0.15 | NS |
Notes:
Castelli risk index I
Castelli risk index II
atherogenic risk index
P<0.05; reference intervals: TC =3.60−6.20 mmol/L; TGs =0.40−2.25 mmol/L; direct HDLC =1.03−1.55 mmol/L; LDLC =0−3.90 mmol/L; VLDLC <0.65 mmol/L; Castelli risk =0.00−4.40; blood pressure =110/70 mmHg; BMI (kg/m2) <18.5 (underweight), 18.5−24.9 (normal weight), >25 (obesity).
Abbreviations: BMI, body mass index; C, control group; CV, cardiovascular; DBP, diastolic blood pressure; HDLC, high-density lipoprotein cholesterol; IC, injectable contraceptive; IMP, implant; LDLC, low-density lipoprotein cholesterol; NS, not significant; OC, oral contraceptive; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; VLDLC, very-low-density lipoprotein cholesterol.